These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 26009011)

  • 41. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.
    Brázdová M; Navrátilová L; Tichý V; Němcová K; Lexa M; Hrstka R; Pečinka P; Adámik M; Vojtesek B; Paleček E; Deppert W; Fojta M
    PLoS One; 2013; 8(3):e59567. PubMed ID: 23555710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.
    Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice.
    Lenfert E; Maenz C; Heinlein C; Jannasch K; Schumacher U; Pantel K; Tolstonog GV; Deppert W; Wegwitz F
    Int J Cancer; 2015 Mar; 136(6):E521-33. PubMed ID: 25195563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chaperone-dependent stabilization and degradation of p53 mutants.
    Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
    Oncogene; 2008 May; 27(24):3371-83. PubMed ID: 18223694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
    Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
    Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
    Zhang Y; Hu Y; Fang JY; Xu J
    Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner.
    Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D
    Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
    Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
    Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
    Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
    Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
    Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP.
    Valentino E; Bellazzo A; Di Minin G; Sicari D; Apollonio M; Scognamiglio G; Di Bonito M; Botti G; Del Sal G; Collavin L
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7623-7628. PubMed ID: 28667123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
    Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
    Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
    Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.
    Amaravadi RK; Yu D; Lum JJ; Bui T; Christophorou MA; Evan GI; Thomas-Tikhonenko A; Thompson CB
    J Clin Invest; 2007 Feb; 117(2):326-36. PubMed ID: 17235397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins.
    Yi T; Qian J; Ye Y; Zhang H; Jin X; Wang M; Yang Z; Zhang W; Wen L; Zhang Y
    ACS Appl Mater Interfaces; 2023 Jan; 15(1):511-523. PubMed ID: 36578131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
    Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
    Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.